The synthetic somatostatin analogue, octreotide, has a longer half-life than native somatostatin, and is effective in inhibition of multiple tumors such as neuroendocrine tumors, gastrointestinal cancer, breast cancer and leukemia [26–28]. The gene discussed is SST; the disease is neuroendocrine neoplasm.